How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity

por Santomasso, Bianca D., Gust, Juliane, Perna, Fabiana
Publicado 2023

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan

por Moss, Nelson S, Tosi, Umberto, Santomasso, Bianca D, Beal, Kathryn, Modi, Shanu
Publicado 2022

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

por Wudhikarn, Kitsada, Palomba, M. Lia, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Devlin, Sean M., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Shah, Gunjan L., Scordo, Michael, Dahi, Parastoo B., Sauter, Craig S., Batlevi, Connie L., Santomasso, Bianca D., Mead, Elena, Seo, Susan K., Perales, Miguel-Angel
Publicado 2020

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

por Brahmer, Julie R, Abu-Sbeih, Hamzah, Ascierto, Paolo Antonio, Brufsky, Jill, Cappelli, Laura C, Cortazar, Frank B, Gerber, David E, Hamad, Lamya, Hansen, Eric, Johnson, Douglas B, Lacouture, Mario E, Masters, Gregory A, Naidoo, Jarushka, Nanni, Michele, Perales, Miguel-Angel, Puzanov, Igor, Santomasso, Bianca D, Shanbhag, Satish P, Sharma, Rajeev, Skondra, Dimitra, Sosman, Jeffrey A, Turner, Michelle, Ernstoff, Marc S
Publicado 2021

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

por Cohen, Adam D., Parekh, Samir, Santomasso, Bianca D., Gállego Pérez-Larraya, Jaime, van de Donk, Niels W. C. J., Arnulf, Bertrand, Mateos, Maria-Victoria, Lendvai, Nikoletta, Jackson, Carolyn C., De Braganca, Kevin C., Schecter, Jordan M., Marquez, Loreta, Lee, Erin, Cornax, Ingrid, Zudaire, Enrique, Li, Claire, Olyslager, Yunsi, Madduri, Deepu, Varsos, Helen, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jakubowiak, Andrzej, Einsele, Hermann, Jagannath, Sundar
Publicado 2022

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

por Lin, Richard J., Lobaugh, Stephanie M., Pennisi, Martina, Chan, Hei Ton, Batlevi, Yakup, Ruiz, Josel D., Elko, Theresa A., Maloy, Molly A., Batlevi, Connie L., Dahi, Parastoo B., Giralt, Sergio A., Hamlin, Paul A., Mead, Elena, Noy, Ariela, Lia Palomba, M., Santomasso, Bianca D., Sauter, Craig S., Scordo, Michael, Shah, Gunjan L., Korc-Grodzicki, Beatriz, Kim, Soo Jung, Silverberg, Mari Lynne, Brooklyn, Chelsea A., Devlin, Sean M., Perales, Miguel-Angel
Publicado 2020

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

por Maus, Marcela V, Alexander, Sara, Bishop, Michael R, Brudno, Jennifer N, Callahan, Colleen, Davila, Marco L, Diamonte, Claudia, Dietrich, Jorg, Fitzgerald, Julie C, Frigault, Matthew J, Fry, Terry J, Holter-Chakrabarty, Jennifer L, Komanduri, Krishna V, Lee, Daniel W, Locke, Frederick L, Maude, Shannon L, McCarthy, Philip L, Mead, Elena, Neelapu, Sattva S, Neilan, Tomas G, Santomasso, Bianca D, Shpall, Elizabeth J, Teachey, David T, Turtle, Cameron J, Whitehead, Tom, Grupp, Stephan A
Publicado 2020

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

por Guidon, Amanda C, Burton, Leeann B, Chwalisz, Bart K, Hillis, James, Schaller, Teilo H, Amato, Anthony A, Betof Warner, Allison, Brastianos, Priscilla K, Cho, Tracey A, Clardy, Stacey L, Cohen, Justine V, Dietrich, Jorg, Dougan, Michael, Doughty, Christopher T, Dubey, Divyanshu, Gelfand, Jeffrey M, Guptill, Jeffrey T, Johnson, Douglas B, Juel, Vern C, Kadish, Robert, Kolb, Noah, LeBoeuf, Nicole R, Linnoila, Jenny, Mammen, Andrew L, Martinez-Lage, Maria, Mooradian, Meghan J, Naidoo, Jarushka, Neilan, Tomas G, Reardon, David A, Rubin, Krista M, Santomasso, Bianca D, Sullivan, Ryan J, Wang, Nancy, Woodman, Karin, Zubiri, Leyre, Louv, William C, Reynolds, Kerry L
Publicado 2021